JULY 7–PRINCETON, N.J.–Laureate Pharma L.P. has expanded its purification capacity with a new automated chromatography system for processing protein products under current good manufacturing practices (cGMPs).

The unit is specifically designed for biopharmaceutical purification applications, featuring polymeric, sanitary flowpaths and an array of detectors. In the coming months, the company anticipates installation and validation of an identically configured larger scale chromatography system to purify protein products produced in its 2,000-liter mammalian cell bioreactor.

“Combined with our process development and manufacturing expertise, this automated, validated, and Part 11 compliant system offers our clients the
confidence that their biopharmaceutical product will be purified accurately and consistently in compliance with cGMPs,” says Bruce Weaver, manager of Protein
Purification at Laureate Pharma. “Our team is looking forward to fully utilizing the new equipment to successfully meet purification requirements presented by our clients.”

Michiel E. Ultee, senior director of Biopharmaceutical Development and Operations, adds that the expansion of is an important step in Laureate Pharma’s mission.

“In addition to supporting the production needs of clients using our 200- and 2,000-liter bioreactors, we also foresee new opportunities for purification,” he says.